WHO guideline on balanced national controlled medicines policies to ensure medical access and safety

Overview

Access to medicines is essential for attainment of universal health coverage, which is central to achievement of the health-related Sustainable Development Goals. Controlled medicines include those such as opioids, benzodiazepines, barbiturates, amphetamines and others with identified or emergent clinical indications. WHO recognizes that these medicines are necessary for pre- and post-operative care, for sedation, for the management of both acute and chronic pain, for palliative care, as anticonvulsants (anti-epileptics), for the management of anxiety disorders and for the management of substance use disorders, including as opioid agonist therapy (OAT).

 

WHO Team
Access to Medicines and Health Products (MHP), Guidelines Review Committee, Health Product Policy and Standards (HPS)
Number of pages
80
Reference numbers
ISBN: 978-92-4-011210-0
Copyright